Details of the Drug
General Information of Drug (ID: DM6FVCE)
| Drug Name |
SERGLIFLOZIN A
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
SERGLIFLOZIN A; UNII-AR34521QFL; CHEMBL270766; AR34521QFL; O-glucoside, 4a; SCHEMBL2574820; BDBM20878; beta-D-Glucopyranoside, 2-((4-methoxyphenyl)methyl)phenyl; HFLCZNNDZKKXCS-OUUBHVDSSA-N; J3.551.075C; 2-(4-methoxybenzyl)phenyl betaD-glucopyranoside; 2-(4-methoxybenzyl)phenyl beta-D-glucopyranoside; 2-(4-methoxybenzyl)-phenyl beta-D-glucopyranoside; 2-(4-methoxy-benzyl)phenyl beta-D-glucopyranoside; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-{2-[(4-methoxyphenyl)methyl]phenoxy}oxane-3,4,5-triol
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 376.4 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.6 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


